{
    "nctId": "NCT00329940",
    "briefTitle": "Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer",
    "officialTitle": "Assessment of Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Having Discontinued Anastrozole Adjuvant Treatment Due to Musculoskeletal Disorders",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "To evaluate the rheumatological tolerability of letrozole 2.5 mg/day in patients treated with anastrozole 1 mg/day",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women receiving anastrozole adjuvant therapy for hormone receptor positive breast cancer who want to interrupt the treatment because of severe rheumatologic adverse events\n* Polymorphonuclear neutrophils (PNN) \u2265 1200/mm3, platelets \u2265 100000/mm3, hemoglobin (Hb) \u2265 10 g/dL\n* Bilirubin \u2264 30 \u03bcmol, SGOT/SGPT \\< 3N\n* Fully signed informed consent\n\nExclusion Criteria:\n\n* Pain due to bone fracture\n* Metastatic disease\n* Hormone therapy other than anastrozole\n* Incapacitating or uncontrolled concomitant disease that could hamper patient's quality of life\n* Hypersensitivity to letrozole or its components\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}